Compare Eli Lilly And Co (LLY) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Synopsys, Inc. — how do they compare? Eli Lilly And Co trades at $1,161.03 (market cap $1.02T), while Synopsys, Inc. trades at $382.37 (market cap $72.47B). The key difference: Eli Lilly And Co is far larger — about 14.1× Synopsys, Inc.'s market cap, and Eli Lilly And Co pays a 0.6% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| LLY | SNPS | |
|---|---|---|
Market Cap | $1.02T | $72.47B |
Sector | Health | Technology |
52-Week High | $1.24K | $645.59 |
52-Week Low | $625.65 | $378.46 |
Enterprise Value | $1.06T | $80.82B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Synopsys (SNPS) trades at $378.47, down 1.51% amid a semiconductor sector downturn. The stock shows bearish technical signals but maintains strong fundamentals with consistent earnings beats and a high analyst buy consensus of 82.76%. Recent news highlights the company's strategic pivot to AI design tools and margin expansion following the Ansys integration.
Outlook remains positive long-term due to SNPS's critical role in AI chip design, though near-term risks include sector volatility and execution of high-margin transitions. The consensus price target of $559.50 implies significant upside, but investors should monitor competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
